{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 19 of 74', 'emerging genetic changes associated with acquired resistance and whether', 'these differ with intermittent therapy', 'the pharmacokinetics of intermittent drug scheduling', '8', 'Selection and withdrawal of patients', '8.1', 'Inclusion Criteria', 'Signed informed consent for the INTERIM trial', 'Aged 18 years old', 'Histologically or cytologically confirmed BRAFV600 mutant stage 3 unresectable', 'or metastatic melanoma', 'Radiologically and/or clinically measurable disease, by RECIST version 1.1;', 'baseline tumour assessments and measurements must be done within 28 days', 'prior to randomisation', 'Eastern Cooperative Oncology Group (ECOG) performance status 0-2', 'Predicted life expectancy >12 weeks', 'Adequate bone marrow function', 'Absolute neutrophil count (ANC) >1.2 X 109/L', 'Haemoglobin (Hb) 90 g/L', 'Platelets >75 X 109 /L', 'White blood cell count (WBC) 2 X 109/L', 'Adequate liver function', 'Aspartate aminotransferase (AST) and/or alanine aminotransferase', '(ALT) 3 X upper limit of normal range (ULN)', 'Total bilirubin <1.5 X ULN (except if the patient has Gilbert Syndrome', 'or liver metastases, in which case the bilirubin must be <3 X ULN)', 'Adequate renal function defined as a serum creatinine <1.5 X ULN or calculated', 'creatinine clearance by Cockcroft-Gault of >40 mL/min', 'Received no prior BRAF or MEK inhibitors for metastatic disease (Prior adjuvant', 'therapy is allowed)', 'Plan to start dabrafenib + trametinib treatment', 'If radiotherapy has previously been given; there is measurable disease which', 'has not been irradiated', 'Willingness and ability to comply with scheduled visits, treatment plans,', 'laboratory tests, completion of QoL questionnaires and other procedures', 'described in the protocol', 'Confirmation of archival tumour tissue sample available', 'Women of child-bearing potential (WCBP) and all sexually active male patients', 'must agree to use effective contraception methods throughout treatment as per', 'section 10.8 of this protocol', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 20 of 74', '8.2 Exclusion Criteria', 'The presence of any of the following will exclude patients:', 'Concomitant immunotherapy being administered to treat advanced melanoma', 'Other invasive malignancies diagnosed within the last year which are not in', 'complete remission, or for which additional therapy is required', 'Significant acute or chronic medical or psychiatric condition, disease or', 'laboratory abnormality which in the judgment of the investigator would place the', 'patient at undue risk or interfere with the trial. Examples include, but are not', 'limited to:', 'Patients with uncontrolled ischaemic heart or other cardiovascular event', '(myocardial infarction (MI), new angina, stroke transient ischaemic attack', '(TIA), or new congestive cardiac failure (CCF)) within the last 6 months', 'Patients with stable but significant cardiovascular disease defined by heart', 'failure (New York Heart Association Functional Classification (NYHF) III or', 'IV, see Appendix 3) or frequent angina. Patients with baseline QTC', 'interval > 480 msec.', 'Presence of active infection', 'Cirrhotic liver disease, known chronic active or acute hepatitis B, or', 'hepatitis C', 'Known allergy or hypersensitivity to dabrafenib or trametinib, or their', 'excipients', 'Women who are pregnant, plan to become pregnant or are lactating during the', 'trial period', 'Other investigational anti-cancer drugs', 'Use of strong inducers and inhibitors of CYP3A or CYP2C8', '8.3', 'Patient consent', 'Patients will be approached to consent to participate in this trial. Individuals who', 'consent to the trial will be requested to complete a Consent Process Patient Experience', 'Survey. Individuals who decline to participate will be invited to complete a separate', 'Patient Experience Survey for individuals who declined, to explore their reasons for', 'declining.', 'Trial-specific screening activities will only be performed after patients have consented', 'to trial participation and signed the informed consent form.', '8.4 Screening Procedures and Pre-randomisation investigations', 'The assessments below must be performed within 28 days prior to randomisation.', 'Patient must give written informed consent prior to any other trial-specific', 'screening activities', 'QoL questionnaires', 'Medical history (including previous and current clinically important diseases and', 'medications) and demographic data', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}